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Abstract 
While mortality following ST-segment elevation myocardial infarction (STEMI) 
is on the decline, the number of patients developing heart failure due to prior 
myocardial infarction (MI) is on the rise. Apart from timely reperfusion by 
primary percutaneous coronary intervention (PPCI), there is currently no 
established therapy for reducing MI size. As such new cardioprotective 
therapies are required to improve clinical outcomes following STEMI. 
Cardiovascular magnetic resonance (CMR) has emerged as an important 
imaging modality for assessing the efficacy of novel therapies for reducing MI 
size and preventing subsequent adverse left ventricular remodeling. The 
recent availability of multi-parametric mapping CMR has provided new 
insights into the pathophysiology underlying myocardial edema, microvascular 
obstruction, intramyocardial hemorrhage, and changes in the remote 
myocardial interstitial space following STEMI. In this article, we provide an 
overview of the recent advances in CMR imaging in reperfused STEMI 
patients, discuss the controversies surrounding its use, and explore future 
applications of CMR in this setting. 
 
Keywords: Cardiovascular magnetic resonance; ST elevation myocardial 
infarction; percutaneous coronary intervention; myocardial infarct size; area-
at-risk; microvascular obstruction; intramyocardial hemorrhage; T1 mapping; 
T2 mapping; T2* mapping; extracellular volume fraction mapping; late 
gadolinium enhancement 
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Introduction 
Improvements in the treatment of patients with acute ST-segment elevation 
myocardial infarction (STEMI) have led to a decline in mortality over the past 
4 decades1, with 1-year cardiac mortality in STEMI patients plateauing at 
around 8%.2 However, morbidity due to post-myocardial infarction (MI) heart 
failure remains significant, and is on the rise.3 The process of reperfusion 
itself can paradoxically induce further myocardial injury and cardiomyocyte 
death, a phenomenon termed ‘myocardial reperfusion injury’.4 There is 
currently no effective therapy for reducing myocardial reperfusion injury, 
despite a wealth of research in this field. This has been partly attributed to 
undertaking clinical studies despite the lack of reproducible and robust 
preclinical data and the design of the clinical cardioprotection studies in terms 
of patient selection and inappropriate timing and mode of delivery of the 
cardioprotective agent.5 As such, the search continues for a novel and 
effective therapy for reducing MI size and preventing heart failure, which can 
be administered as an adjunct to PPCI following STEMI. Cardiovascular 
magnetic resonance (CMR) has emerged as an important imaging modality 
for assessing the cardioprotective efficacy of novel therapies for reducing MI 
size and prevent adverse left ventricle (LV) remodeling in reperfused STEMI 
patients.6, 7 It is currently the gold standard imaging modality for quantifying MI 
size,8 and is able to detect small subendocardial MI (as little as 1 gram)9 with 
good accuracy.10  
With the recent availability of native T1, T2, T2* and post-contrast T1-
mapping (to derive extracellular volume fraction [ECV] mapping)11, more in-
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depth insights can be obtained into the pathophysiological processes such as 
the evolution of myocardial edema in the first week post-STEMI12, 13, the 
chronic manifestation of intramyocardial hemorrhage, and its prognostic 
significance over microvascular obstruction14, 15 and changes in the remote 
myocardial interstitial space in those developing adverse LV remodeling16, 17 
following STEMI. In this article, we provide an overview of some of the recent 
advances in CMR imaging in reperfused STEMI patients, discuss the recent 
controversies surrounding its use, and explore future applications of CMR in 
this setting. 
 
Basic concepts 
In this section, we provide a brief description of some of the basic concepts 
concerning the use of CMR in STEMI. Table 1 provides an explanation of the 
more technical terms used throughout this article. Figure 1a also provides an 
illustration of the various components of the myocardium that can be 
interrogated by CMR. 
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Table 1: Technical descriptions of the various components of the myocardium assessed by CMR in STEMI 
Components Technical description 
Native T1, post-contrast 
T1 and ECV  
This is the time constant to recover 63% of its longitudinal magnetization (spin–lattice relaxation) and is expressed in milliseconds. 
It is referred to as native T1 when performed prior to the administration of gadolinium chelate. 11 
It is recommended that post-contrast T1 be performed at least 10 minutes following contrast administration.11  
Once the native and post-contrast T1 of the blood and myocardium and the hematocrit are known, the ECV can be calculated 
using the formula below 11: 
ECV (%) = (100–hematocrit) x (1/post-contrastT1myocardium) - (1/nativeT1myocardium) 
                                          (1/post-contrastT1blood) - (1/nativeT1blood) 
T2 This refers to the constant representing the decay of transverse magnetization (spin-spin relaxation) to 37% of its initial equilibrium 
value and it is expressed in milliseconds. 11 
T2* This is the time constant representing the decay of transverse magnetization in the presence of local magnetic field 
inhomogeneities and is expressed in milliseconds. 11 
Parametric mapping A process where an anatomical map is generated with each pixel representing a specific magnetic tissue property (T1, T2, or T2* 
or ECV) derived from the spatially corresponding voxel of a set of co-registered magnetic resonance source images. 11 
MI size This refers to the mass or volume of infarcted myocardium, and is conventionally quantified by late gadolinium enhancement.  
After 10 minutes, pseudo-equilibrium of gadolinium chelate concentration between blood and well-perfused myocardium develops. 
During this time, a higher concentration of contrast is distributed in areas of acute or chronic MI (significantly shortening T1) than 
in normal myocardium. Therefore, with appropriate nulling of the remote myocardium using inversion recovery T1-weighted 
sequences, the necrotic or scarred areas appear bright.6, 18 
Early microvascular 
obstruction 
This can be identified as areas of dark core within the MI zone using first-pass perfusion or EGE imaging performed with a fixed, 
high TI (e.g. 440 to 500ms at 1.5T), acquired at 1-4 minutes post-contrast injection. 
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Late microvascular 
obstruction 
This can be identified as a dark core within the areas of hyperenhancement on conventional late gadolinium enhancement 
sequences acquired >10 minutes post-contrast injection. 
Intramyocardial 
hemorrhage 
This can be identified using T2* -weighed imaging or T2*-mapping.  
From brain imaging data, the degradation of the extravasated erythrocytes to oxyhemoglobin, deoxyhemoglobin, and 
methemoglobin (strongly paramagnetic) is dynamic and exhibits different magnetic properties at various stages as previously 
described by Bradley and colleagues.19 Breakdown of the erythrocyte membrane eventually leads to ferritin and hemosiderin 
deposits within the macrophages and the iron-degradation products can be detected using T2* imaging. 
Most studies have used a cut-off value for T2*of < 20ms14, 20 to detect intramyocardial hemorrhage but a threshold-based method 
of 2 standard deviations below the mean remote myocardial T2* can also be used.21 In centers where T2* imaging is not available, 
many studies have also used T2-weighted imaging but its diagnostic performance is less robust than T2*-weighted imaging.22 
Area-at-risk This refers to the territory supplied by the infarct-related artery and includes both the reversibility injured myocardial (the salvaged 
myocardium) and the infarcted myocardium. The area-at-risk can be indirectly assessed by CMR using late gadolinium 
enhancement imaging (to derive the endocardial surface area)23, T2-weighted imaging24, 25, T2-mapping26, 27, native T1-mapping27, 
28, early gadolinium enhancement imaging29, 30, pre-contrast SSFP cine31, and post-contrast SSFP cine imaging32, 33  
T1 and T2-mapping are currently considered the most robust of the CMR techniques as they have better contrast-to-noise ratio 
than the T2-weighted/ T1-weighted/ cine imaging techniques; they are less prone to blood pool and motion artifacts; and they are 
less likely to suffer from signal drop-out due to surface coil inhomogeneities.26, 28, 34 
Myocardial Salvage and 
myocardial salvage 
index 
Myocardial salvage can be calculated by subtracting the MI size from the area-at-risk. 
The myocardial salvage index refers to the ratio of the myocardial salvage to the area-at-risk. 35 
Remote myocardium This is usually defined as a myocardial segment 180° from the infarcted territory. 36 
ECV: extracellular volume fraction; EGE: early gadolinium enhancement; CMR: cardiovascular magnetic resonance; SSFP: steady 
state free precession 
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Myocardial Infarct Size  
 MI size refers to the infarcted myocardium and is conventionally 
quantified by late gadolinium enhancement (Table 1 and Figure 1b).37 The 
gadolinium chelate cannot cross the intact cell membranes.37 Following acute 
myocardial necrosis, the cell membranes are ruptured allowing the contrast 
agent to enter these cells. In the chronic setting, there is also expansion of the 
extracellular space due to the collagen deposits and the relatively low residual 
amount of intact cardiomyocytes in the region of the infarct. Therefore, 
following gadolinium chelate administration, the contrast redistributes itself 
from the vascular compartment to the interstitial space and at pseudo-
equilibrium a higher concentration of contrast is distributed in areas of acute 
or chronic MI  than in normal myocardium. 18 (Table 1). 
 
Microvascular Obstruction and Intramyocardial Hemorrhage 
Microvascular obstruction refers to the inability to reperfuse the 
coronary microcirculation in a previously ischemic region, despite opening the 
epicardial vessel.38 Microvascular obstruction can be identified as a dark 
hypo-intense core within the areas of hyper-enhancement on either early 
gadolinium enhancement (referred to as early microvascular obstruction) or 
conventional late gadolinium enhancement sequences (referred to as late 
microvascular obstruction) - defined in Table 1 and illustrated in Figure 1b.  
If the coronary microvasculature injury following STEMI is especially 
severe, and the integrity of the vessels are damaged, the extravasation of red 
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blood cells into the myocardium can occur - termed intramyocardial 
hemorrhage.14 The breakdown products of hemoglobin within the myocardium 
can be detected as a hypo-intense core39 within the MI zone on T2*-imaging 
or T2*-mapping (Figures 1 and 2). Of the two approaches, T2*-mapping has 
been shown to have greater sensitivity for detecting intramyocardial 
hemorrhage following STEMI when compared to T2-mapping (Table 1).40 41   
A small study previously showed that the hypointense core on the T1 or 
T2 maps could provide an alternative method to detect intramyocardial 
hemorrhage in cases where T2* is not available or not interpretable (Figures 1 
and 2)39 and further studies are needed to confirm these findings.  
  
Area-at-risk  
The area-at-risk refers to the territory supplied by the infarct-related 
artery that would have infarcted following STEMI, if reperfusion had not taken 
place to salvage viable myocardium. The area-at-risk includes both the 
reversibility injured myocardium (also referred to as the salvaged 
myocardium) and the infarcted myocardium. Figure 3 shows an example of 
the edema-based area-at-risk by T1 and T2-mapping and the corresponding 
MI size on late gadolinium enhancement in a patient presenting with an acute 
inferior STEMI treated by PPCI.  
A number of CMR approaches to delineating the area-at-risk following 
STEMI have been described (see Table 1). However, they all have their 
limitations,42 and although each technique has been validated against 
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histology in the preclinical setting24, 27, 30, 31, 33, there is currently no consensus 
on which CMR method should be used to quantify the area-at-risk in the 
clinical setting. So far, no studies have compared these techniques, head-to-
head, in the same patient cohort. Once the area-at-risk and MI size are 
known, the myocardial salvage index can be calculated as described in Table 
1. 
The myocardial salvage index is considered a more sensitive measure 
for assessing the efficacy of novel cardioprotective therapies, when compared 
to MI size alone35, as it normalizes the MI size reduction to the area-at-risk, 
the latter of which varies from patients to patient. As such, the myocardial 
salvage index may help to reduce sample size for clinical cardioprotection 
studies in comparison to using MI size alone.36  
 
Recent advances in the role of CMR in reperfused STEMI patients  
In this section, first of all, we will summarize the advances in the use of T1 
mapping to assess MI size. We will then elaborate how CMR has improved 
our understanding of the relationship between microvascular obstruction and 
intramyocardial hemorrhage; and the role of MI size, intramyocardial 
hemorrhage, residual myocardial iron and the remote myocardium in the 
development of adverse LV remodeling. Finally, we will explore the prognostic 
significance of these CMR-derived indices in the reperfused STEMI patients. 
 
T1-mapping for the quantification of MI size 
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Post-contrast T1-mapping has recently emerged as a promising 
technique for the quantification of MI size, as an alternative to conventional 
late gadolinium enhancement imaging. Bulluck and colleagues43 recently 
showed that post-contrast T1-mapping can accurately quantify acute MI size 
in a small group of STEMI patients, obviating the need to perform late 
gadolinium enhancement imaging. Recent studies have also investigated 
whether native T1-mapping (pre-contrast) can assess MI size. Kali and 
colleagues44  showed that chronic MI (median of 13.6 years post-MI) could be 
detected using native T1-mapping at 3T in a small cohort of 25 patients. Liu 
and colleaguesl45 showed that native T1-mapping at 3T could also identify 
acute MI size. However, only 58 short-axis T1 maps without microvascular 
obstruction were analyzed in that study.45 These findings are of great interest 
as one could potentially perform a comprehensive CMR study in STEMI 
without the need of contrast agent and this approach would also significantly 
shorten the scan time and make CMR available to a wider range of patients.  
Whether ECV on an acute CMR scan can estimate final MI size 
following STEMI has recently been investigated. Garg and colleagues46 
showed that an ECV value of 0.46 or above could predict chronic MI size from 
the acute ECV maps. However, Bland-Altman analysis showed a bias of 1.9% 
and wide limits of agreement of ±10.5% and further studies are therefore 
needed to build on these findings.47 However, as it stands, ECV-mapping may 
complement late gadolinium enhancement imaging to assess MI size and 
predict wall motion recovery at follow-up, as recently shown by 2 small 
studies.16, 48  
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Despite the promises of T1-mapping in STEMI for measuring MI size, 
the published studies have been small, and from single-centers. Larger 
studies are therefore required to confirm these findings, using different field 
strengths, mapping sequences, and vendors, before they can be more widely 
adopted. 
 
Relationship between microvascular obstruction and intramyocardial 
hemorrhage  
Serial CMR imaging of STEMI patients in the first few days following 
PPCI has provided evidence that the incidence and extent of microvascular 
obstruction and intramyocardial hemorrhage vary with time. The extent of late 
microvascular obstruction has been reported to peak at 4-12 hours, to remain 
stable the first 2 days and to reduce in size by day 10 following STEMI.14 
Furthermore, in those patients with microvascular obstruction persisting at 
one week, Orn and colleagues49 showed that they were more likely to develop 
adverse LV remodeling compared to those with microvascular obstruction at 
day 2 only. On the other hand, the detection of intramyocardial hemorrhage 
has been shown to peak at day 3, and to reduce in incidence by day 10 
following PPCI.12   
Hamirani and colleagues40 showed that intramyocardial hemorrhage 
(detected by either T2-weighted imaging or T2* imaging) was more strongly 
associated with late microvascular obstruction (R=0.89 to 0.93) than with 
early microvascular obstruction (R=0.30). Using the more robust method of 
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T2*-mapping for the detection of intramyocardial hemorrhage, Carrick and 
colleagues14 in 286 patients showed that all patients with intramyocardial 
hemorrhage also had late microvascular obstruction.  
Based on these recent studies14, 40, 50, 51, it appears that early 
microvascular obstruction occurs in around 60-65%; late microvascular 
obstruction in around 50-55%; and intramyocardial hemorrhage in around 35-
40% of reperfused STEMI patients. However, the detection of microvascular 
obstruction and intramyocardial hemorrhage is dependent on the CMR 
techniques, the timing of imaging, and the definitions used. 
 
Acute MI size and subsequent adverse LV remodeling  
Conventional theory assumes that the larger the MI size, the higher the 
LV wall stress, and the LV therefore dilates to maintain the stroke volume as a 
compensatory mechanism (via the Frank-Starling principle). However, LV 
dilation, as described by the Laplace relationship, leads to further wall stress 
and begets more LV dilation, in the absence of compensatory LV hypertrophy. 
Westman and colleagues52 have recently proposed that there is an imperfect 
association between MI size and adverse LV remodeling. They showed in 122 
STEMI patients, that 15% of those with MI size <18.5% developed adverse 
LV remodeling, and 40% of those with MI size ≥18.5% developed adverse LV 
remodeling. However, Westman and colleagues52 used a definition of 
>10ml/m2 increase in indexed LV end-diastolic volume  in their study. A more 
appropriate definition for adverse LV remodeling post-STEMI by CMR may be 
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a cut-off value of 12% change in LV end-diastolic volume.53 This study also 
showed an imperfect association between acute MI size and adverse LV 
remodeling, and between the presence of microvascular obstruction and 
adverse LV remodeling.53 Some patients with large MI size and microvascular 
obstruction developed reverse LV remodeling and whereas other patients with 
small MI size and no microvascular obstruction also developed adverse LV 
remodeling.53 As eluded to by Westman and colleagues52,  the development 
of adverse LV remodeling is complex and multi-factorial and an excessive 
inflammatory response together with MI size may play an important role 
following STEMI.  
 
Residual myocardial iron and adverse LV remodeling 
There are emerging data that intramyocardial hemorrhage at the time 
of PPCI leads to residual myocardial iron during the convalescent phase, and 
it may be a source of prolonged inflammation and impact on adverse LV 
remodeling.54 Kali and colleagues54 showed in a small cohort of 15 STEMI 
patients and in 20 canines (with histological validation) that intramyocardial 
hemorrhage resulted in residual myocardial iron within the MI zone, and this 
provided a source of prolonged inflammatory burden in the chronic phase. 
These findings were recently confirmed in a canine model of MI, and the 
extent of residual iron was strongly correlated with markers of inflammation 
and adverse LV remodeling.55 Roghi and colleagues56 found higher levels of 
non-transferrin bound iron in 7 out of 15 STEMI patients with microvascular 
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obstruction and postulated that intramyocardial hemorrhage could be a source 
of cardiotoxicity in these patients.  
In a small cohort of STEMI patients, Bulluck and colleagues15 recently 
found that intramyocardial hemorrhage and subsequent residual myocardial 
iron at follow-up were associated with persistently elevated T2 values in the 
surrounding infarct tissue and with adverse LV remodeling.15 Carberry and 
colleagues57 have recently confirmed these findings in a cohort of 203 STEMI 
patients. They showed that 36% of their cohort had intramyocardial 
hemorrhage by T2*-mapping and 59% of those had residual myocardial iron 
at 6 months. Residual myocardial iron was associated with adverse LV 
remodeling at 6 months and worse clinical outcomes after a median follow-up 
of 4 years.57 Figure 4a shows an example of a patient with an acute inferior 
STEMI treated by PPCI, and with late microvascular obstruction and 
intramyocardial hemorrhage despite restoring normal flow in the epicardial 
coronary artery during PPCI. At follow-up, there was residual myocardial iron 
and persistently elevated T2 values in the areas surrounding the residual iron, 
which may represent persistent myocardial inflammation.  
 
The role of the remote myocardium and clinical outcomes 
Whether changes in the extracellular matrix in the remote myocardium 
(Table 1) in STEMI patients treated by PPCI are associated with adverse LV 
remodeling, has been a topic of on-going research.16, 17, 58-60 Using automated 
ECV maps, Bulluck and colleagues16 have showed in a small cohort of 40 
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STEMI patients that ECV in the remote myocardium was acutely elevated, 
and this elevation in ECV persisted in those who developed adverse LV 
remodeling at 5 months, suggesting that remote compensatory changes in the 
extracellular matrix occurred in this subset of patients. The increase in acute 
ECV could have been due to an increase in the intravascular compartment as 
a compensatory mechanism. At follow-up, the increase in ECV likely 
represented diffused interstitial fibrosis, as part of the remodeling process. 
Garg and colleagues60 recently confirmed these findings in a cohort of 50 
STEMI patients. Furthermore, they also showed that remote segments with 
ECV expansion were associated with impaired wall thickening. In a larger 
cohort of patients (n=131), Carberry and colleagues17 showed that the change 
in ECV of the remote myocardium was a multivariable associate of the 
change in LV end-diastolic volume at 6 months. Whether this change in ECV 
could independently predict those at risk of adverse events remains to be 
tested in future, adequately powered studies. Figure 4b shows an example of 
the paired acute and follow-up (6 months) late gadolinium enhancement and 
automated ECV maps with representative regions of interest of the remote 
myocardium of a patient with an anterior STEMI treated by PPCI. 
Carrick and colleagues59 demonstrated that higher native T1 of the remote 
myocardium of 267 reperfused STEMI patients on the acute CMR scan was 
associated with changes in LV end-diastolic volume from baseline to 6 
months, and it was independently associated with adverse cardiac events 
after a median follow-up of 845 days. Most recently, in a similar number of 
patients, Reinstadler and colleagues58 also showed that the remote native 
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myocardial T1 was independently associated with adverse events, after 
adjusting for clinical risk factors and other CMR variables after a follow-up of 6 
months.  
Therefore, T1 mapping has the potential to completement clinical and other 
CMR-derived parameters to improve the risk-stratification of STEMI patients 
and warrants further investigation in a multi-center setting. 
 
Acute MI size and clinical outcomes  
Morbidity and mortality post-STEMI is closely related to acute MI size. A 
recent meta-analysis of 2,632 patients showed that MI size measured by 
CMR or SPECT within a month post-PPCI from 10 randomized controlled 
trials (RCTs) was strongly associated with 1-year hospitalization for heart 
failure and all-cause mortality.61 For every 5% increase in MI size, there was a 
20% increase in the relative hazard ratio for 1-year hospitalization for heart 
failure and all-cause mortality. The event rate was 1.2% in those with MI size ≤ 
8% of the LV and there was a stepwise increase to 2.5% in those with MI size 
>8% - ≤ 17.9% of the LV; 5.6% in those with MI size >17.9% - 29.8% of the 
LV; and 8.8% in those with MI size >29.8% of the LV. This study adds to the 
growing body of evidence that acute MI size is prognostic, and therefore 
remains a valid surrogate endpoint for clinical trials. However, this study also 
highlights the fact that one of the limitations of using CMR in RCTs is that 
there is an element of selection bias as only those patients fit enough to 
tolerate a CMR study would enter these RCTs and the overall event rates 
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were 2.2% and 2.6% for of all-cause mortality and hospitalization for heart 
failure at 1 year, respectively, much lower than those reported from clinical 
registries. 2, 3 
  
Microvascular obstruction and intramyocardial hemorrhage and clinical 
outcomes  
Both microvascular obstruction and intramyocardial hemorrhage are 
associated with larger MI size, adverse LV remodeling, and worse clinical 
outcomes.40, 50 In a meta-analysis of more than 1000 patients, Van 
Kranenburg and colleagues50 showed that the presence of microvascular 
obstruction was an independent predictor of major adverse clinical outcome at 
2 years in STEMI patients, whereas MI size was not independently associated 
with adverse events. There was a graded reduction in event-free survival in 
patients with MI size <25% of the LV, with and without microvascular 
obstruction, and those with MI size >25% of the LV, with and without 
microvascular obstruction. The prognostic value of microvascular obstruction 
over MI size for mortality and hospitalization for heart failure was recently 
confirmed by de Waha and colleagues51 in a pooled analysis of patient-level 
data from 7 randomized controlled trials (n=1688) at 1 year and by Symons 
and colleagues62 in a longitudinal study of 810 patients following a median 
follow-up of 5.5 years.  
Early studies showed that intramyocardial hemorrhage, detected by 
T2-weighted images, was closely related to the development of adverse LV 
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remodeling and worse clinical outcomes.40 Most recently, using T2*-mapping, 
Carrick and colleagues14 showed that intramyocardial hemorrhage was more 
closely associated with adverse clinical outcomes than microvascular 
obstruction.  
Therefore, based on the current evidence discussed so far, the prognosis 
worsens with larger MI size. Patients with larger MI size are also more likely to 
have microvascular obstruction and intramyocardial hemorrhage. The 
prognosis is worse for STEMI patients with microvascular obstruction when 
compared to those without microvascular obstruction63 and is worst for those 
with microvascular obstruction and intramyocardial hemorrhage.14  
Currently, there are no effective methods to detect those at risk of 
microvascular obstruction and intramyocardial hemorrhage at the time of 
PPCI. Amier and colleagues64 recently showed that anterior STEMI and use 
glycoprotein IIb/IIIa inhibitors were associated with the development of 
intramyocardial hemorrhage. However, this was a retrospective post-hoc 
analysis and intramyocardial hemorrhage was identified using T2-weighted 
imaging instead of the more robust T2*-weighted imaging and their findings 
need to be confirmed in future studies. Furthermore, there are no established 
therapies to prevent or minimize the burden of microvascular obstruction and 
intramyocardial hemorrhage in the clinical setting4, although promising results 
are emerging in the preclinical setting.65 
 
Current controversies in CMR imaging of STEMI patients 
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Is myocardial edema confined to the infarct zone or does it extend into the 
salvaged myocardium? 
In the 1980s, Higgins and colleagues66 were the first to study myocardial T2 
CMR in a canine model of MI. Interestingly, both T2 and T1 were shown to 
change similarly in the setting of an acute MI. The observed changes were 
theoretically consistent with myocardial edema, and correlated with the 
measurements of myocardial water content estimated by wet-weight to dry-
weight ratios. The changes in myocardial T2 have been attributed to a 
combination of an increase in absolute tissue water, movement of water from 
the extracellular to the intracellular compartment, and the conversion of 
protein-bound water to free water.67  
Not all experimental and clinical studies have supported the concept 
that the region of hyper-intensity on T2-weighted images delineates the area-
at-risk. Aletras and colleagues24 and Tilak and colleagues68 validated the 
edema-based area-at-risk using T2-weighted images against microsphere in 
reperfused and non-reperfused canine MI. Ubach and colleagues69 showed 
that the area-at-risk derived from T2-weighted imaging matched that obtained 
from single-photon emission computed tomography, both in animals with and 
without late gadolinium enhancement.  
In contrast, Kim and colleagues70 reported that T2-weighted imaging 
did not depict the area-at-risk in anesthetized dogs that were subjected to 
different durations of coronary occlusion. MI size by late gadolinium 
enhancement was compared to the gold standard method of triphenyl 
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tetrazolium chloride staining, and area-at-risk by T2-weighted imaging was 
compared to the gold-standard method of fluorescent microspheres, 4 days 
after reperfusion. The T2-weighted hyper-intensity correlated and matched in 
shape better with the MI size than with the area-at-risk, and these findings 
were confirmed in a small group of acute MI patients. Although the findings 
from the canine model of MI may be due to the presence of well-developed 
collaterals in that species, the T2-weighted sequence in that study was 
different to what has been used so far by other studies.24, 68 In the clinical 
setting, using hybrid positron emission tomography/CMR imaging in 
reperfused STEMI patients, Bulluck and colleagues71 recently showed that the 
area of reduced 18F-fluorodeoxyglucose uptake was significantly larger than 
the MI size and closely matched the area-at-risk delineated by T2-mapping on 
the acute scan, supporting the notion that T2-mapping does delineate both 
the reversibly and the irreversibly injured myocardium within the area-at-risk71. 
In addition, the areas of reduced 18F-fluorodeoxyglucose uptake within the 
salvaged myocardium within the area-at-risk were no longer present on a 
follow-up scan several months later.71 Hammer-Hansen and colleagues72 
have provided further insights on this topic, using a canine model of MI. They 
showed that T2 values were elevated both in the MI zone and salvaged 
myocardium, and they were both significantly higher than the T2 values in the 
remote myocardium. 
Therefore, the majority of the current literature supports the notion that 
edema, assessed by CMR using T2-mapping, occurs both in the irreversibly 
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and reversibly injured myocardium during the first week of a reperfused 
STEMI in the clinical setting.26, 28, 71, 73 
 
Dynamic changes in the edema-based area-at-risk during the first week in 
reperfused STEMI patients 
It was initially believed that the extent of myocardial edema was stable 
in the first week in STEMI patients73, 74, although both these studies only 
performed T2-weighted imaging on days 1 and 7. Emerging evidence 
suggests that the extent of myocardial edema is dynamic. Hammer-Hansen 
and colleagues72 have shown in a canine model of reperfused MI, that at 2 
hours, T2 values were higher in both the infarcted and salvaged myocardium 
when compared to those who had the scan at 48 hours, highlighting that the 
extent of myocardial edema within the first few days of an MI is dynamic.  
Fernandez-Jimenez and colleagues75 studied the interplay between 
myocardial water content (using desiccation) and T2 relaxation times in a 
porcine model of reperfused MI. They reported a ‘bimodal’ pattern of edema, 
appearing at 2 hours, resolving by 24 hours and then reappearing on day 4 
and peaking at day 7. The first wave of edema was attributed to myocardial 
reperfusion injury, and the second wave of edema was attributed to 
inflammation during the tissue-healing phase.76 However, they did not take 
into account the presence of microvascular obstruction and intramyocardial 
hemorrhage, which may have interfered with their T2 measurements, and 
they had a small sample size of 5 pigs at each time point. Furthermore, the 
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same animals were not serially scanned. Most recently, Fernandez-Jimenez 
and colleagues13 showed that the bimodal edematous response of the infarct 
related territory was present in humans as well. However, they used the less 
robust T2-weighted imaging modality instead for both quantifying the extent of 
the edema-based area-at-risk and for detecting intramyocardial hemorrhage. 
It was not clear how many of their 14 patients had intramyocardial 
hemorrhage in that cohort. Furthermore, on a patient-level basis (their 
supplementary material figures 3 and 4), not all patients displayed a bimodal 
response for of the intensity and extent of edema in the infarct-related 
territory. 
It was initially believed that edema is stable in the first week of an MI.73, 
74 However, both these studies only performed T2-weighted imaging on days 
1 and 7 and the peak in the edema-based area-at-risk shown by Carrick and 
colleagues12 on day 3 was therefore not identified by the previous 2 studies.73  
In contrast to these studies, in a cohort of 30 patients with serial 
imaging, Carrick and colleagues12 found that the extent of myocardial edema 
was maximal at day 3, and decreased by day 10 following PPCI, suggesting a 
unimodal peak in myocardial edema in the first few days following reperfusion. 
Interestingly, in STEMI patients with intramyocardial hemorrhage, they did 
observe a bimodal pattern in T2 and T2* values within the MI core, whereas in 
patients without intramyocardial hemorrhage, only a unimodal pattern in T2 
and T2* values was observed, suggesting that the presence of 
intramyocardial hemorrhage may have been responsible for the apparent 
bimodal edema pattern in T2 and T2* values.  
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Nordlund and colleagues32 recently provided some evidence that there 
was no bimodal pattern of edema in the clinical setting. They combined data 
from 3 studies involving 215 patients and showed there were no difference in 
size, quality of the T2-weighted images and the ability to detect the culprit 
territory when patients having a CMR study on Day 1 to Day 6 onwards were 
compared. ,  
 Given the dynamic changes in the extent of edema and acute MI size 
over the first few days following STEMI, it is important that future clinical 
cardioprotection studies define the time-window for performing the acute CMR 
scan in order to optimize the quantification of both acute MI size and AAR. 
There is currently no consensus on the optimal timing for performing the acute 
CMR scan although 3-5 days6 and 4-7 days13 post-PPCI have been proposed.  
 
Cardioprotective therapies and the edema-based area-at-risk in reperfused 
STEMI patients  
The utility of T2-weighted imaging for quantifying the area-at-risk has been put 
into question because certain cardioprotective therapies have been shown to 
reduce not only MI size, but the extent of myocardial edema measured by T2-
weighted and T2-mapping imaging. Ischemic postconditioning77 and remote 
ischemic conditioning using transient arm or leg ischemia and reperfusion) 78 
have been shown to reduce both MI size and the extent of edema delineated 
by T2-mapping and T2-weighted imaging, leading to an underestimation of 
the area-at-risk by these techniques. However, these were small studies of 
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reperfused STEMI patients and they were not adequately powered to assess 
that endpoint. Intuitively, the fact that a cardioprotective therapy can reduce 
MI size, it should be expected to also limit the extent of myocardial edema, 
which itself is the result of myocardial ischemia and reperfusion injury.  
However, in a recently published large study of 696 STEMI patients by 
Eitel and colleagues79, ischemic postconditioning or a combination of remote 
ischemic conditioning and ischemic postconditioning did not reduce the extent 
of myocardial edema when compared to the control arm. Furthermore, drugs 
such as metoprolol80 and exenatide81 that were effective at increasing the 
myocardial salvage index did not reduce the extent of myocardial edema. One 
potential explanation for this discrepancy could be that those therapies that 
are potent enough to reduce MI size in reperfused STEMI patients, are 
capable to reduce the extent of myocardial edema. In contrast, those 
therapies that are less potent and do not reduce MI size, and only increase 
myocardial salvage, do not affect the extent of myocardial edema. Either way, 
these findings may question the use of edema-based area-at-risk measured 
by CMR to assess myocardial salvage in clinical cardioprotection studies.   
 
The optimal timing of late gadolinium enhancement imaging for acute and 
chronic MI size quantification 
Acute MI size has been shown to be dynamic and to decrease 
significantly in size between Day 1 and Day 7 post-STEMI.82 In a recent study 
by Carrick and colleagues12, MI size was shown to be similar between days 1 
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and 3, and reduced in size by day 10. Jablonowski and colleagues83 recently 
provided some mechanistic insights into this phenomenon in a porcine model 
of acute MI. At day 1, they found higher ECV values in the peri-infarct zone 
that could be due to severe edema or a mixture of infarcted and salvaged 
myocardium in that area that contributed to the overestimation of MI size. By 7 
days, the ECV values in the peri-infarct zone decreased to the same level as 
the rest of the salvaged myocardium, such that MI size assessed by late 
gadolinium enhancement matched that by histology. 
Acquiring late gadolinium enhancement too early (<8 minutes post–
contrast administration) can result in an overestimation of MI size84, and 
acquiring late gadolinium enhancement at 25 minutes for acute MI size has 
been shown to be a better predictor of LV recovery.85 However waiting 25 
minutes post-contrast administration may be difficult to apply in the clinical 
setting due to time constraints, and would affect workflow. As such, late 
gadolinium enhancement images are currently acquired 10-15 minutes post-
contrast6 as a compromise. 
Several studies have already shown a significant regression in MI size 
(by 30-35%) occurring between the acute CMR scan and the chronic phase.49, 
86, 87 There are several factors responsible for this observation. First of all, the 
composition of the different tissues being identified by late gadolinium 
enhancement in the acute (myocardial necrosis compounded with edema, 
intramyocardial hemorrhage and microvascular obstruction) and chronic 
phase (focal replacement fibrosis) is different. The regression of MI size 
between the acute, sub-acute and chronic phases therefore represents the 
27 
 
gradual resolution of edema, intramyocardial hemorrhage and microvascular 
obstruction and the gradual replacement of the necrotic cardiomyocytes with 
focal scars.73, 87  
 As it stands, the optimal timing of CMR for MI size is not well 
established but late gadolinium enhancement appears to stabilize by 10 days 
post the index event.12 In most centers, STEMI patients with an 
uncomplicated inpatient stay are discharged within the first week. Logistically, 
this would mean that patients would have to come back for the CMR scan and 
this may lead to a proportion of patients dropping out.6 Efforts are underway 
to attempt to standardize the acquisition of CMR for clinical cardioprotection 
studies.6 
 
Future directions 
The need to standardize the use of CMR in reperfused STEMI patients 
Both acute and chronic MI sizes by CMR have been shown to be stronger 
predictors of clinical outcomes when compared to LV ejection fraction or LV 
volumes.88, 89 Therefore, due to the robustness and high reproducibility of 
CMR to quantify MI size10, 37 90 88, 89, both acute and chronic MI size are 
increasingly being used as surrogate endpoints for randomized control trials 
assessing the effectiveness of new cardioprotective therapies, and can 
reduce the sample size required.6 However, acute MI size is influenced by a 
number of factors including the timing of the CMR scan, the dose of contrast 
used, the time elapsed following contrast administration and acquisition of late 
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gadolinium enhancement imaging and the method used for the quantification 
of MI size.6, 91 Therefore, there is an urgent need for the CMR community to 
come up with a consensus position to standardize the acquisition of late 
gadolinium enhancement imaging and the quantification of MI size in future 
studies.6 This would no doubt help to strengthen the robustness of this 
technique and would also facilitate prospective or retrospective collaborative 
research with merging of CMR data from different centers around the world. 
 
Towards improving the tolerability and accessibility of CMR in reperfused 
STEMI patients 
There have already been some advances in free-breathing and motion 
corrected T292 and T2*-mapping93 and late gadolinium enhancement 
imaging94 negating the need for breath-holding and helping to accelerate the 
acquisition of these sequences. Other developments in real-time cine imaging 
for LV ejection fraction and future refinements in CMR fingerprinting 
techniques (for robust and fast acquisition of simultaneous T1 and T2-
mapping data per slice within one breath-hold) will further reduce scan time, 
and will be highly desirable in the acute STEMI setting. These developments 
would make CMR, which is currently confined to those fit enough to lie inside 
the scanner for at least 30-45 minutes, accessible to a wider number of 
patients. Furthermore, reducing the duration of the scan to 20-30 minutes 
could also potentially reduce the cost of a scan, and improve the participation 
of more centers in STEMI-related CMR research. However, most of these 
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new developments are still in the validation phase and are not available to all 
CMR vendors and platforms.  
The use of gadolinium chelates is not recommended in those with a 
glomerular filtration rate < 30 mL/min/1.73m2, to minimize the risk of 
nephrogenic systemic fibrosis, and constitutes a contraindication in CMR-
based clinical cardioprotection studies. Furthermore, the Food and Drug 
Administration (FDA) has recently issued a new warning regarding gadolinium 
remaining in patients’ brainstem, for months to years after receiving these 
drugs. However, gadolinium retention has not been directly linked to adverse 
events in patients with normal renal function and the current benefits of using 
gadolinium chelates outweigh any potential risks. Therefore, the potential for 
non-contrast CMR imaging such as T1 mapping20 and T2* mapping14 to 
provide adequate prognostic information over post-contrast imaging 
modalities and that could be applied to all patients, irrespective of renal 
function, warrants further investigation. 
 
CMR as a tool to risk-stratify and guide management in STEMI patients at risk 
of developing adverse LV remodeling and subsequent heart failure 
A number of cardioprotective therapies have had promising results in the 
experimental setting for reducing MI size and preventing adverse LV 
remodeling, but have failed to be translated into the clinical setting.95 A more 
targeted approach using CMR to identify those most at risk (e.g. according to 
their acute MI size or according to the presence or absence of microvascular 
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obstruction) may improve the translation of those promising experimental 
results in the clinical setting, to prevent adverse LV remodeling and reduce 
the onset of heart failure in these patients. Stiermaier and colleagues96 and 
Pontone and colleagues97 most recently proposed CMR risk scores to identify 
those at high risk of adverse events. Their approach would be ideal to identify 
high-risk patients but the CMR indices and cut-off values included in each 
study differed and further validation work is required to build on their findings. 
Furthermore, CMR could identify those with intramyocardial hemorrhage, and 
they could be targeted with anti-inflammatory agents or chelation therapy15, 98, 
to minimize the cardiotoxic effects of the residual iron (which has been shown 
to occur in two-third of patients with intramyocardial hemorrhage from a 
pooled analysis of 4 studies)57 during the convalescent phase of an acute 
STEMI and this warrants further investigation.  
 
CMR as a tool for risk-stratification of STEMI patients at risk of arrhythmic 
events 
The current guidelines recommend an implantable cardioverter defibrillator 
(ICD) for primary prevention in those with symptomatic heart failure and 
LVEF<35% 40 days following the index event.99 However, mortality within the 
first 30 days post-MI has been shown to be the highest 100 but is 
predominantly believed to be due to MI or myocardial rupture.101 Despite that, 
a quarter of those deaths are still due to ventricular arrhythmias 101 and 
currently there is no established tool to risk stratify these patients in the acute 
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phase of an MI. Acute MI size (cut-off of 23.5g/m2 or 31% of the LV) in 
combination with LVEF (cut-off of 36%) by CMR within the first week on an MI 
has been shown to predict adverse arrhythmic cardiac events at 2 years.102 
Other studies have shown that CMR in the chronic phase could also be used 
to predict sudden cardiac death using the peri-infarct zone extent 103 or 
chronic MI size 104 in combination with LVEF. Furthermore, residual 
myocardial iron as a consequence of intramyocardial hemorrhage has also 
been shown to be pro-arrhythmic.105 Although all these were relatively small 
and single-center studies, CMR has shown promise to improve the risk-
stratification of STEMI patients at risk of ventricular arrhythmias. With the 
availability of inline, automated ECV-mapping106 and free-breathing T2*-
mapping93, characterization of the infarct size and peri-infarct zone and infarct 
core may become more objective and CMR would play an invaluable role to 
identify those most likely to benefit from a primary prevention ICD in a near 
future.  
 
Conclusion 
Over the last few years, CMR scans performed in the acute phase of 
reperfused STEMI have improved our understanding of the changes occurring 
in the infarcted, salvaged, and remote myocardium, and have provided 
insights into the impact of MI size, microvascular obstruction and 
intramyocardial hemorrhage on clinical outcomes. There are ongoing 
controversies surrounding the use of CMR to delineate the area-at-risk, and 
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the dynamic changes in myocardial edema in the first few days following 
PPCI. However, more work is ongoing and CMR holds promise to become 
accessible to more patients, and to be used as a tool to risk-stratify patients, 
guide treatment, and improve clinical outcomes post-PPCI in the near future.  
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CMR in STEMI Figures 
Figure 1: (a) Schematic representation of the different components of 
the myocardium in a patient with reperfused STEMI and; (b) methods for 
delineating the area-at-risk, MI size, microvascular obstruction and 
intramyocardial hemorrhage by CMR 
Figure 1a illustrates the various components of the myocardium in a 
reperfused STEMI patient that can be assessed by CMR, namely the area-at-
risk, salvaged myocardium, the area of hyperenhancement and the 
hypointense core on late gadolinium enhancement images and the remote 
myocardium. The MI size includes both the areas of hyperenhancement and 
the hypointense core on late gadolinium enhancement images. The 
hypointense core on late gadolinium enhancement represents microvascular 
obstruction and a proportion of patients would also have intramyocardial 
hemorrhage within these areas (areas of low T2* on T2*-weighted images or 
mapping). The area-at-risk is a combination of both the MI size and the 
salvaged myocardium. 
Figure 1b illustrates the CMR-based methods and their timing during CMR 
acquisition for delineating the area-at-risk, MI size, microvascular obstruction 
(early and late) and intramyocardial hemorrhage. The most robust method for 
demarcating the area-at-risk currently is T1 and T2-mapping. Late gadolinium 
enhancement is the gold standard for detecting MI size and late microvascular 
obstruction. T2*-mapping is currently the gold standard to detect 
intramyocardial hemorrhage. The table provides an indication of the abilities 
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of each sequence to detect each components of an MI by STEMI and graded 
as: ✔✔✔: Robust, have been shown by several studies; ✔✔: Possible, have 
been shown by some studies; ✔: Theoretically possible and/or have only been 
shown by 1-2 studies 
MVO: microvascular obstruction; IMH: intramyocardial hemorrhage; EGE: 
early gadolinium enhancement; LGE: late gadolinium enhancement; ESA: 
endocardial surface area 
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Figure 2: The infarct core of a patient with microvascular obstruction 
and intramyocardial hemorrhage 
This figure shows an example of a patient with an acute anterior STEMI 
treated by PPCI and the CMR images on day 4 showing the infarct core on 
the late gadolinium enhancement images representing microvascular 
obstruction and on the T2*, T1 and T2 maps representing intramyocardial 
hemorrhage (arrows). 
LGE: late gadolinium enhancement 
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Figure 3: Delineation of the edema-based area-at-risk by T1 and T2-
mapping, and MI size by late gadolinium enhancement that can be used 
to calculate myocardial salvage and myocardial salvage index 
The top panel shows an example of the edema-based area-at-risk by T1 and 
T2-mapping (indicated by black arrows) and the corresponding MI size on late 
gadolinium enhancement (red arrow) in a patient with an inferior STEMI 
treated by PPCI, with the CMR images acquired on day 3 post-reperfusion. 
The bottom panel shows the corresponding post-process images using a 
threshold-based method to delineate the area-at-risk (threshold of 2 standard 
deviations) and MI size (threshold of 5 standard deviations) as the highlighted 
areas with the areas of hypointense core included as part of the area-at-risk 
and MI size. The myocardial salvage (area-at-risk subtract the MI size) and 
myocardial salvage index (myocardial salvage as a ratio of the area-at-risk) 
can be retrospectively calculated from a single CMR scan. 
LGE: late gadolinium enhancement 
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Figure 4: (a) Paired acute and follow-up T2* and T2 maps; (b) Paired 
acute and follow-up automated ECV maps of a patient with an inferior 
STEMI 
This figure shows an example of the paired acute and follow-up (6 months) 
late gadolinium enhancement and automated ECV maps, T2* and T2 maps of 
a patient with an inferior STEMI, treated by PPCI with restoration of normal 
flow in the infarct-related epicardial coronary artery. The arrows show the area 
of microvascular obstruction with intramyocardial hemorrhage. The 
corresponding ECV maps show the area of microvascular obstruction where 
contrast fails to penetrate the areas of microvascular obstruction and appears 
as pseudo-normal myocardium on the acute scan. At follow-up, the 
microvascular obstruction has resolved and the space previously occupied by 
the microvascular obstruction has very high ECV (white areas within the MI 
zone corresponding to the upper limit of the look-up color scale). The white 
regions of interest on the ECV maps (black arrows) are representative areas 
of the remote myocardium that can be used to assess changes in the 
extracellular matrix. There was residual myocardial iron at follow-up and 
persistently elevated T2 in the areas surrounding the residual iron (blue 
arrows on the follow-up images. 
LGE: late gadolinium enhancement 
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